Recruiting

Cold Atmospheric Plasma on Peritoneal Tumor Tissue

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

J-plasma

Device
Who is being recruted

Over 18 Years
+3 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Basic Science Study

Interventional
Study Start: August 2024
See protocol details

Summary

Principal SponsorUniversity Hospital, Ghent
Study ContactWim Ceelen, professorMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: August 21, 2024

Actual date on which the first participant was enrolled.

This study explores a new method called Cold Atmospheric Plasma (CAP) to see how it affects tumor tissue in patients with peritoneal metastases, a type of cancer that spreads to the lining of the abdomen. The research is important because it aims to find out if CAP can be effective in weakening or killing cancer cells, which could improve treatment options for patients undergoing surgery for this condition. Understanding the effects of CAP on tumors could lead to better strategies for managing and possibly improving outcomes for patients with this type of cancer. Participants in the study will have their tumor nodules treated with CAP for varying lengths of time and at different intensities before the tumors are surgically removed. After removal, the nodules will be examined to assess the vitality of the tumor cells, meaning how alive or dead the cancer cells are after treatment. This process helps researchers determine how well CAP works against the tumor tissue. The study does not specify any particular risks or benefits of CAP yet, as it focuses on understanding its basic effects on cancer cells.

Official TitleEffects of Cold Atmospheric Plasma (CAP) on Peritoneal Tumor Tissue
NCT06796634
Principal SponsorUniversity Hospital, Ghent
Study ContactWim Ceelen, professorMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

5 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Basic Science Study

Basic science studies help researchers understand how the body works or how a disease develops. They don't test treatments, but they build the foundation for future therapies.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

3 inclusion criteria required to participate
Patients with peritoneal metastases undergoing surgery (CRS, debulking), irrespective of the origin. Potential cancer types include ovarian cancer, colorectal cancer, and malignant peritoneal mesothelioma
Written informed consent
Age ≥ 18 years.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
* Surgery and application of CAP: at the start of surgery, an inventory is made of suitable tumor nodules that will be planned for resection. Nodules should have a maximal size of 2-3 mm, since it is unlikely that bigger lesions can be adequately treated with CAP. * Selected tumor nodules will be treated with the J-plasma device at the standard settings (Helium gas flow of 4 l/min, coagulation and cutting intensity at 35). The distance between the tip of the device and the tissue will be approx. 10 mm. Using a timer and footswitch, nodules will be treated at different power settings and durations: * 15 W, 30W, or 45W * 2, 5, or 10 seconds. * The treated nodules will be resected at least 30 minutes after plasma treatment, and the exact timing will be documented. The samples are split in half: one half is fixed in formalin for histology and immune histochemistry, and the other half is immediately processed for live/death staining using flow cytometry.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

UZ Ghent

Ghent, BelgiumOpen UZ Ghent in Google Maps
Recruiting
One Study Center